[18F]FLT PET for Non-Invasive Monitoring of Early Response to Gene Therapy in Experimental Gliomas

被引：0
作者：
Maria A. Rueger
Mitra Ameli
Hongfeng Li
Alexandra Winkeler
Benedikt Rueckriem
Stefan Vollmar
Norbert Galldiks
Volker Hesselmann
Cornel Fraefel
Klaus Wienhard
Wolf-Dieter Heiss
Andreas H. Jacobs
机构：
[1] Max Planck-Institute for Neurological Research,Laboratory for Gene Therapy and Molecular Imaging
[2] Center for Molecular Medicine (CMMC),Departments of Neurology
[3] University Hospital Cologne,Department of Radiology
[4] University Hospital Cologne,European Institute for Molecular Imaging (EIMI)
[5] University of Münster,undefined
来源：
Molecular Imaging and Biology | 2011年 / 13卷
关键词：
[18F]FLT PET; Glioma; Suicide gene therapy; HSV-1-;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The purpose of this study was to investigate the potential of 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) positron emission tomography (PET) to detect early treatment responses in gliomas. Human glioma cells were stably transduced with genes yielding therapeutic activity, sorted for different levels of exogenous gene expression, and implanted subcutaneously into nude mice. Multimodality imaging during prodrug therapy included (a) magnetic resonance imaging, (b) PET with 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine assessing exogenous gene expression, and (c) repeat [18F]FLT PET assessing antiproliferative therapeutic response. All stably transduced gliomas responded to therapy with significant reduction in tumor volume and [18F]FLT accumulation within 3 days after initiation of therapy. The change in [18F]FLT uptake before and after treatment correlated to volumetrically calculated growth rates. Therapeutic efficacy as monitored by [18F]FLT PET correlated to levels of therapeutic gene expression measured in vivo. Thus, [18F]FLT PET assesses early antiproliferative effects, making it a promising radiotracer for the development of novel treatments for glioma.
引用
收藏
页码：547 / 557
页数：10
相关论文
共 213 条
  • [1] de Wit MC(2004)Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression Neurology 63 535-537
  • [2] de Bruin HG(2000)Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment Radiology 217 377-384
  • [3] Eijkenboom W(1998)Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1334-1336
  • [4] Sillevis Smitt PA(2002)3-Deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules Cancer Res 62 3331-3334
  • [5] van den Bent MJ(2003)3′-18F-Fluoro-3′-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med 44 1927-1932
  • [6] Kumar AJ(2003)Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer Eur J Nucl Med Mol Imaging 30 988-994
  • [7] Leeds NE(2003)3′-[18F]Fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease Cancer Res 63 2681-2687
  • [8] Fuller GN(2005)Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG J Nucl Med 46 945-952
  • [9] Van Tassel P(2005)[(18)F]3′-Deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors Eur J Nucl Med Mol Imaging 32 653-659
  • [10] Maor MH(2005)18F-Fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors J Nucl Med 46 1948-1958
12345678910